VIRACTA THERAPEUTICS INC (VIRX)
US92765F1084 - Common Stock
Taking everything into account, VIRX scores 1 out of 10 in our fundamental rating. VIRX was compared to 565 industry peers in the Biotechnology industry. While VIRX seems to be doing ok healthwise, there are quite some concerns on its profitability. VIRX is valued expensive and it does not seem to be growing.
1. Profitability
1.1 Basic Checks
In the past year VIRX has reported negative net income.
In the past year VIRX has reported a negative cash flow from operations.
VIRX had negative earnings in each of the past 5 years.
VIRX had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
The Return On Assets of VIRX (-144.74%) is worse than 84.85% of its industry peers.
VIRX has a Return On Equity of -1697.34%. This is amonst the worse of the industry: VIRX underperforms 83.78% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -144.74% | ||
| ROE | -1697.34% | ||
| ROIC | N/A |
ROA(3y)-82.33%
ROA(5y)-80.57%
ROE(3y)-160.27%
ROE(5y)-134.85%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
VIRX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
Compared to 1 year ago, VIRX has more shares outstanding
Compared to 5 years ago, VIRX has more shares outstanding
Compared to 1 year ago, VIRX has a worse debt to assets ratio.
2.2 Solvency
Based on the Altman-Z score of -17.73, we must say that VIRX is in the distress zone and has some risk of bankruptcy.
VIRX has a worse Altman-Z score (-17.73) than 83.96% of its industry peers.
VIRX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -17.73 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
VIRX has a Current Ratio of 1.08. This is a normal value and indicates that VIRX is financially healthy and should not expect problems in meeting its short term obligations.
VIRX's Current ratio of 1.08 is on the low side compared to the rest of the industry. VIRX is outperformed by 86.99% of its industry peers.
A Quick Ratio of 1.08 indicates that VIRX should not have too much problems paying its short term obligations.
Looking at the Quick ratio, with a value of 1.08, VIRX is doing worse than 85.20% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.08 | ||
| Quick Ratio | 1.08 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an nice 15.94% over the past year.
EPS 1Y (TTM)15.94%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%21.88%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
VIRX is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 13.13% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y32.77%
EPS Next 2Y23.48%
EPS Next 3Y19.86%
EPS Next 5Y13.13%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
VIRX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for VIRX. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
VIRX's earnings are expected to grow with 19.86% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y23.48%
EPS Next 3Y19.86%
5. Dividend
5.1 Amount
No dividends for VIRX!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
VIRACTA THERAPEUTICS INC
NASDAQ:VIRX (11/21/2024, 8:00:02 PM)
After market: 0.1529 +0 (+0.66%)0.1519
0 (0%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap5.99M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -144.74% | ||
| ROE | -1697.34% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 1.08 | ||
| Quick Ratio | 1.08 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)15.94%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y32.77%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y